Daily News Analysis (Free subscription) | 07/23/2008
Dr Reddy's Laboratories may have lost a $100 million profit opportunity with the US Court of Appeals for the Federal Circuit on Monday
Patent Docs (Free subscription) | 07/22/2008
By Kevin E. Noonan -- Sanity may be returning to the Federal Circuit's treatment of two issues, obviousness and inequitable conduct. In Eisai Co. v. Dr. Reddy's Laboratories, Inc., the Court (in an opinion by Judge Rader joined by Judges Linn and Proust) affirmed the District Court's determination that the patent-in-suit, U.S. Patent No. 5,045,552 was not obvious and was not obtained through inequitable...
Red Orbit (Free subscription) | 07/22/2008
TOKYO and WOODCLIFF LAKE, N.J., July 21 /PRNewswire/ -- With respect to Eisai's patent infringement lawsuit against Teva Pharmaceuticals and Dr. Reddy's Laboratories concerning Aciphex(R) (generic name: rabeprazole sodium tablets, Product Name in Japan: Pariet(R)), Eisai Co., Ltd. and its U.S.
The Telegraph India (Free subscription) | 07/21/2008
Mumbai, July 21: Dr Reddy's Laboratories (DRL) will buy out the stakes of Citigroup Venture Capital and ICICI Venture Funds Management Company in research and development firm Perlecan Pharma.
Market Watch (Free subscription) | 07/21/2008
LONDON (MarketWatch) -- Indian generic drugmaker Dr. Reddy's Laboratories said Monday that net profit in its fiscal first quarter ending June 30 fell 28% to $31 million, or 19 cents a share, from $43 million, or 25 cents a share a year earlier. Revenue for the period rose 25% to $350 million under U.S. generally accepted accounting principles. The group said revenue growth was driven by its key markets...
Business Wire (Free subscription) | 07/21/2008
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) today announced its unaudited financial results for the quarter ended June 30,
Business Wire (Free subscription) | 07/18/2008
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Limited (NYSE:RDY) announces that the company’s annual report on
Business Wire (Free subscription) | 07/15/2008
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories (NYSE:RDY) will announce results for the First Quarter ended June 30, 2008 on Monday, July 21, 2008 after the Board Meeting. The
Scotsman.com (Free subscription) | 07/10/2008
AQUAPHARM, the Oban-based marine biotechnology company, has announced a new licensing agreement with Cambridge-based Dr Reddy's Laboratories.
Market Wire (Free subscription) | 07/09/2008
MATAWAN, NJ (MARKET WIRE) SpeechSwitch, Inc. (OTCBB: SSWC), a leader in speech-recognition technology, announced today that Dr. Reddy's Laboratories, Inc. has installed a Speech Enabled Auto Attendant at their corporate headquarters building. SpeechSwitch, Inc. ("SpeechSwitch") previously was a wholly owned subsidiary of iVoice, Inc. (OTCBB: IVOI) prior to the spin-off from iVoice that was completed...
Indian Express (Free subscription) | 07/09/2008
Dr Reddy's Laboratories announced that it has signed a global distribution agreement for Ibuprofen API with NYSE-listed Albemarle Corporation a US-based specialty chemicals company.
Hindu (Free subscription) | 07/09/2008
HYDERABAD: Dr. Reddy’s Laboratories has signed a global distribution agreement for Ibuprofen API (active pharmaceutical ingredient) with Albemarle Corporation, a Louisiana-based (U.S.) specialty chemicals company. The agreement would ...
Daily News Analysis (Free subscription) | 07/08/2008
Circa 2006. Dr Reddy's Laboratories acquired Germany's fourth largest generics manufacturer Betapharm Arzneimittel for $570 million.
Business Wire (Free subscription) | 06/13/2008
DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (
Financial Services (Free subscription) | 06/09/2008
Mkts: SKF India, Lupin post smart gains @ 13:10 hrsSify, India - 44 minutes agoMax India, Dr. Reddy's Laboratories and India Bulls Financial Services are up with modest gains. Suzlon Energy, BPCL, Unitech, Jaiprakash Associates, HDFC, …
